Do you have a question or suggestion?

Fill out the form and we will contact you as soon as possible. Thank you for your interest!

 

 

Main Contacts  Pro EuroDILINet

General enquiries: info@proeurodilinet.eu


Dr Raul ANDRADE
Chair

Prof Guruprasad AITHAL
Vice Chair

Dr Rossella MAGLI
Science officer

Ms Nathalie WARENGHIEN
Administrative officer

Dr. Michael Merz

Dr. Michael Merz

WORKING GROUP 2. DILI RISK STRATIFICATION

Deputy for Leader WG2 (michael.merz@t-online.de)

University Hospital Zurich (Switzerland)

 

  • Clinical Pharmacologist and Drug Safety Expert
  • 1993-1998: Quintiles Research, Freiburg, Germany
  • 1998-2017: Novartis Pharma AG, Basel, Switzerland
    • Head Modeling and Simulation, Clinical Pharmacology
    • Global Safety Profiling Director, Exploratory Clinical Development
    • Section Head Systems Toxicology & Head Safety Networks, Translational Sciences
    • Chair investigative Liver Expert Team, Novartis Institutes for BioMedical Research
  • 2010-2016: Project coordinator IMI SAFE-T consortium for clinical safety biomarker qualification
  • Since 05/2017: Independent consultant, focus on Drug-Induced Liver Injury; Consortium Coordinator at University Hospital Zürich, Switzerland
  • In charge of proposal H2020-JTI-IMI2-2017-13-two-stage: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease